Buy Liptinib 250 Lapatinib IP

Liptinib 250 is a 250mg tablet containing Lapatinib IP, used for targeted cancer therapy. This oral medication supports treatment in specific oncology protocols. Suitable for ambient storage, it offers a 300-tablet pack size for extended use.

Strength

250mg

Pack Size

300s

Storage

Ambient

Manufacturer / TM Owner

OncoZest

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Uses / Indications

Liptinib 250 is primarily used in oncology to support certain cancer treatment protocols. It belongs to a class of medications that target specific pathways in cancer cells. Patients often use it alongside other therapies as part of a broader treatment plan. This medication is not a standalone cure but may be prescribed for specific conditions.

Side Effects

Liptinib 250 may help manage symptoms associated with certain cancer treatments by targeting affected cells. Users often report a reduction in treatment-related discomfort over time. Common effects include mild gastrointestinal changes or fatigue, which vary by individual. Regular monitoring is recommended to assess its impact.

Precautions & Warnings

Store Liptinib 250 at room temperature, away from moisture and direct light. Keep out of reach of children and pets. Do not use if the packaging is damaged or the tablets appear altered. Consult a healthcare provider before starting or stopping this medication, especially if pregnant or breastfeeding.

Avoid Interactions

Liptinib 250 may interact with other medications, including strong CYP3A4 inhibitors or inducers. Avoid grapefruit products while using this medication, as they can affect its metabolism. Discuss all current medications with a healthcare provider to minimize risks. Alcohol use should be limited or avoided.

References

Frequently Asked Questions

Liptinib 250 is used in oncology to support certain cancer treatment protocols as part of a broader therapy plan.

Store Liptinib 250 at room temperature, away from moisture and direct light, in its original packaging.

Consult a healthcare provider before combining Liptinib 250 with other medications to avoid potential interactions.

Pregnant or breastfeeding individuals should consult a healthcare provider before using Liptinib 250.

Common effects may include mild gastrointestinal changes or fatigue, which vary by individual.

Published by GNH India Pharmaceuticals Limited

Last updated: 18 May 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.